GGrantIndex
Sort

51,593 grants matching hepatitis

Toward Safer Gene Therapy for Hemophilia A

$2,492,072
Roland W. Herzog · Indiana University Indianapolis · P01 · FY2024 · HL

Translational Immunology Research and Accelerated [vaccine] Development (TRIAD)

$2,490,625
Anne Searls De Groot · University Of Rhode Island · U19 · FY2012 · AI

Southern Liver Health Cohort

$2,489,960
Cathrine Hoyo · North Carolina State University Raleigh · UH3 · FY2023 · CA

Caribbean, Central and South America network for HIV epidemiology (CCASnet)

$2,488,424
Catherine C McGowan · Vanderbilt University · U01 · FY2013 · AI

Vanderbilt HIV Clinical Trials Unit

$2,487,433
David W Haas · Vanderbilt University Medical Center · UM1 · FY2020 · AI

Biogenesis and Catabolism of Atherogenic Lipoproteins

$2,485,299
M Mahmood Hussain · Nyu Long Island School Of Medicine · P01 · FY2023 · HL

Epidemiology and Natural History of Cancer-Associated Viruses

$2,483,980
Sam M Mbulaiteye · Division Of Cancer Epidemiology And Genetics · ZIA · FY2009 · CA

AIDS Linked to the IntraVenous Experience (ALIVE)

$2,480,863
Shruti H Mehta · Johns Hopkins University · U01 · FY2022 · DA

A vaccine design to induce protective B and T cell immunity against hepatitis C virus

$2,479,615
Steven Foung · Stanford University · U19 · FY2023 · AI

General Clinical Research Center

$2,478,297
Sheldon M Retchin · Virginia Commonwealth University · M01 · FY2007 · RR

Regulation of hepatic and systemic immune responses

$2,472,718
Barbara Rehermann · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2022 · DK

CLINICAL AND LABORATORY STUDIES OF MALIGNANT LYMPHOMAS

$2,471,663
Stanford University · P01 · FY2004 · CA

Pitt-Ohio State Clinical Trials Unit

$2,468,833
John W Mellors · University Of Pittsburgh At Pittsburgh · UM1 · FY2023 · AI

Biogenesis and Catabolism of Atherogenic Lipoproteins

$2,467,924
M Mahmood Hussain · New York University D/B/A Nyu Long Island School Of Medicine · P01 · FY2025 · HL

RNA INTERFERENCE AS A WEAPON AGAINST BIOTERRORISM

$2,467,065
Immune Disease Institute, Inc. · U19 · FY2004 · AI

Philadelphia HIV Therapeutics and Prevention Clinical Trials Unit

$2,464,363
Pablo Tebas · University Of Pennsylvania · UM1 · FY2020 · AI

IN VITRO ANTIVIRAL SCREENING PROGRAM-HEPATITIS C & B VIRUS

$2,459,894
Michael Murray · · N01 · FY2007 · AI

Endocannabinoids And Energy Homeostasis

$2,457,470
George Kunos · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2011 · AA

Weill Cornell Medical College-New Jersey Medical School Clinical Trials Unit

$2,456,647
Roy M Gulick · Weill Medical Coll Of Cornell Univ · UM1 · FY2014 · AI

Washington Metropolitan Women's Interagency HIV Study

$2,455,223
Mary A Young · Georgetown University · U01 · FY2012 · AI

Triglycerides, Diabetes and Cardiovascular Disease

$2,453,240
Karin E. Bornfeldt · University Of Washington · P01 · FY2024 · HL

TREATMENT OF ADDICTIONS--BIOLOGICAL CORRELATES

$2,451,962
Rockefeller University · P50 · FY2000 · DA

Durable Alteration of the Human Immune system after Infection or Immunotherapy

$2,446,152
Raymond T Chung · Massachusetts General Hospital · U19 · FY2024 · AI

Xenobiotic receptors

$2,445,645
Frank J Gonzalez · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA

Johns Hopkins University Baltimore India Clinical Trail Unit (JHUBI CTU)

$2,442,720
Amita Gupta · Johns Hopkins University · UM1 · FY2025 · AI